Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Consorcio busca una pyme especializada en péptidos como agentes terapéuticos o de diagnóstico para participar en un proyecto de la convocatoria EuroTransBio

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDDE20161103001
Publicado:
09/11/2016
Caducidad:
09/11/2017
Resumen:
Una pyme alemana del sector de bioinformática busca pymes con el fin de participar en un proyecto de la convocatoria EuroTransBio. El objetivo es desarrollar un método que permita utilizar datos de secuenciación de la próxima generación y datos vinculantes de alto rendimiento de procesos de selección combinatoria empleados en el desarrollo de nuevos agentes biológicos para predecir estructuras biológicas optimizadas, incluyendo nuevos algoritmos. El socio se encargará de seleccionar nuevos agentes biológicos, ofrecer bibliotecas de secuenciación y realizar ensayos funcionales con los candidatos. La fecha límite de la convocatoria es el 31 de enero de 2017 y el plazo para presentar expresiones de interés finaliza el 9 de diciembre de 2016.


Details

Tittle:
Consortium seeks SME specialized in peptids as therapeutics or diagnostics for EuroTransBio Project (12th transnat. call)
Summary:
A bioinformatic SME from Germany is searching for SME partners for a project in the EuroTransBio 12th transnat. call on method allowing to use next-generation sequencing and high throughput binding data of combinatorial selection procedures used for the development of new biologics to predict optimized biological lead structures, incl. new algorithms. The partner should perform selections for new biologics, provide enriched libraries for sequencing, and perform functional tests with candidates.
Description:
The objective of the project is to develop innovative algorithms based on deep learning (machine learning) techniques to use available sequence and functional data to predict optimized biologics in silico. The basis for this method will be developed by using peptides as a model case but will be extended to more complex proteins like antibodies in a second phase. The final product is a user-friendly software, which allows researchers the in silico optimization of their biologics under development in house.

Users are pharmaceutical or biotech companies as well as academic research groups active in the development of novel biologics (therapeutics or diagnostics).

The company and two other German partners (universities) have the expertise in the development of algorithms and software, deep learning methods, NGS analysis and chip-based high-throughput binding analysis of initial candidates.

The partner SME, which is sought to complement the consortium, should have programs for the development of peptides (pure or enclosed in a scaffold), provide enriched libraries for NGS, and perform secondary functional tests of selected peptides in its own systems. The partner would greatly benefit by enhancing its own research programs and having access to our bioinformatic know-how.

Details for EuroTransBio 12th transnational call that applies here:

The partner SME should be located in Austria, Flanders (Belgium), Finland, France (Alsace, Champagne-Ardenne and Lorraine), Italy, or Russia due to the restrictions of the current EuroTransBio 12th transnational call.

The deadline for EOIs is 9th of December 2016 (although earlier EOIs are highly encouraged because of the winter holidays).

The deadline for the submission of the proposal is January 31st, 2017.

Anticipated start of the project is in the middle of 2017.
Advantages and Innovations:
The problem: Next-generation sequencing (NGS) analysis is a powerful method to identify even rare ligands in in vitro selection experiments for novel biologics amongst millions of candidates. However, these data just represent a small fraction of all possible lead molecules. Thus, initial ligands have to be optimized for optimal function but also for cost-effective production in a laborious and expensive lead optimization process. Frequently, not the best biological product is found.

The solution which will be developed in this project is to combine for the first time the existing sequencing data with functional data in a high-throughput fashion with the aim to predict optimized lead candidates in silico. This innovative method (novel algorithms) will be integrated in an intuitive, user-friendly software, which enables non-bioinformaticians an easy access to take advantage of big data to develop better products.


Stage of Development:
Proposal under development
Technical Specification or Expertise Sought:
The consortium is looking for SMEs which are specialized in peptides as therapeutics or diagnostics and which have active product development projects. Larger peptides such as antibodies will not be considered for this project.

The specifics of the peptides to be considered for this project are:

1) Peptides with a maximum length of 20, the shorter the better

2) Peptides enclosed in a scaffold (like microproteins), the fewer interdependent peptide-loops the better

3) Or multicycles (bi- or tricyclic systems connected by cysteine)

4) As well as for the high-throughput measurements on arrays: peptides with a maximum length of 20, again: the shorter the better

For other classes of substances: check is necessary by consortium, in which flow rate they can be synthesized and purified for assays on arrays as well as assays in liquid.
IPR Status:
Secret Know-how,Copyright
Comments Regarding IPR Status:
Main product of the company is software, which cannot be protected by patents. Software itself is protected by copyrights, specific algorithms as secret know how.

Partner sought

Partner Sought:
A partner is sought who brings an actual development project (diagnostic or therapeutic) into the cooperation since they will not only profit in their development efforts, but the novel product is an additional innovation within the grant project. This should be beneficial for enhancing the chances of success in the EuroTransBio call. The partner should develop the peptides as described under technical specifications by selection methods like phage, yeast, or bacterial display and provide enriched libraries for next-generation sequencing analysis and the target molecule for binding analysis. The SME partner that is sought will do the bioinformatic analysis and identify enriched sequence families. A German partner (university) will test the candidates in a chip-based high-throughput format for binding kinetics. These data are used to develop algorithms by means of machine learning (deep learning) to suggest optimized sequence candidates, which should exhibit better binding kinetics but are as well optimized for other properties, e.g. effective production (2nd German partner university). The partner, who is sought here, should further test the candidates in his functional assays and provide the data for further optimization of the algorithms. The consortium leader will do the final development of the software.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Dissemination

Restrict dissemination to specific countries:
Austria
Belgium
Finland
France
Italy
Russian Federation

Programme-call

Evaluation Scheme:
Single Stage
Coordinator Required:
No
Deadline for Call:
31/01/2017
Project Duration:
156